About us Vision Management Position Careers
Management
Prof. Dr. Heinz-Herbert Fiebig
our Chief Executive Officer, was appointed Prof. of Medical Oncology and Hematology in 1990 at the Medical Faculty of the University of Freiburg. He conducted numerous Phase I and II clinical studies within the CESAR Clinical Trials Study Groups. His main areas of research and expertise are discovery and preclinical evaluation of novel anticancer agents. He founded Oncotest GmbH in 1992, a preclinical CRO well known for its unique collection of patient derived tumor models which considerably improved the way to realize preclinical evaluation of novel anticancer agents. With his team he investigated numerous targeted and cytotoxic anticancer drugs for pharmaceutical and biotech companies as well as in academic collaborations. Oncotest GmbH was acquired by Charles River Laboratories in November 2015 when Prof. FIEBIG decided to use his experience in anticancer drug discovery to start a new venture: 4HF Biotec GmbH.
Prof. FIEBIG is author in more than 350 scientific publications. He was awarded the Czerny price of the German Society for Hematology and Oncology and the price of the German Ministry of Health for reducing animal experiments in cancer research.
Dr. Vincent Vuaroqueaux
our Chief Technology Officer (CTO), earned his PhD at the University of Aix-Marseille with his research in molecular oncology. His postdoctoral work related to translational research and cancer biomarker development at the Assistance Publique-Hopitaux de Marseille. During 2002-2007, he worked as molecular biology platform leader at Oncoscore and at the Stiftung Tumor Bank Basel for breast and prostate cancers companion diagnostics development. He joined Oncotest in 2007 as lab head for development of molecular diagnostics, thereby predicting patient’s responses to anticancer agents such as Avastin and Cetuximab. He became responsible for the department of biomarker development and bioinformatics at Oncotest in 2011 and coordinated its activities in molecular biology, protein analytics, histology and bioinformatics. With his team, he realized the characterization of Oncotest’s tumor models and ran multiple large OMICS molecular characterization programs as well as numerous biomarker discovery projects in collaboration with pharmaceutical companies, hospitals and academic centers.
Dr. VUAROQUEAUX is a member of the AACR and is author/co-author of numerous publications and presentations. He joined 4HF Biotec as CTO in January 2017 thereby focusing on the identification of new drug targets, selective inhibitors and predictive biomarkers.